GlobeNewswire: Xeris Pharmaceuticals, Inc. Contains the last 10 of 56 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:00:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/27/1992241/0/en/Xeris-Pharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2019-Financial-Results-and-Host-Conference-Call-on-March-11-2020.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 20202020-02-27T21:05:00Z<![CDATA[CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and full year 2019 financial results before the opening of the U.S. financial markets on Wednesday, March 11, 2020. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial and operational results.]]>https://www.globenewswire.com/news-release/2020/02/12/1983493/0/en/Xeris-Pharmaceuticals-Announces-Pricing-of-Public-Offering-of-Shares-of-Common-Stock.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock2020-02-12T00:06:51Z<![CDATA[CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $4.15 per share, before underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $37.4 million. All shares of common stock will be offered by Xeris. The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2020/02/10/1982633/0/en/Xeris-Pharmaceuticals-Announces-Proposed-Public-Offering-of-6-000-000-Shares-of-Common-Stock.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock2020-02-10T21:06:13Z<![CDATA[CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All shares of common stock will be offered by Xeris. Xeris expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2019/12/27/1964715/0/en/Xeris-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2019-12-27T21:05:00Z<![CDATA[CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on December 24, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 14,500 shares of its common stock to 3 new employees under Xeris’ Inducement Equity Plan.]]>https://www.globenewswire.com/news-release/2019/11/29/1954182/0/en/Xeris-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2019-11-29T18:05:00Z<![CDATA[CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 27, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 8,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan.]]>https://www.globenewswire.com/news-release/2019/11/21/1950626/0/en/Xeris-Pharmaceuticals-Provides-a-Business-Update-During-Recent-Investor-Conference.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference2019-11-21T11:00:00Z<![CDATA[MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program discontinued based on Phase 2 results]]>https://www.globenewswire.com/news-release/2019/11/07/1943101/0/en/Xeris-Pharmaceuticals-Reports-Third-Quarter-2019-Financial-Results-and-Highlights.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights2019-11-07T13:00:00Z<![CDATA[Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription]]>https://www.globenewswire.com/news-release/2019/11/01/1939782/0/en/Xeris-Pharmaceuticals-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2019-11-01T20:05:00Z<![CDATA[CHICAGO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 30, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 81,000 shares of its common stock to 61 new employees under Xeris’ Inducement Equity Plan.]]>https://www.globenewswire.com/news-release/2019/10/01/1923237/0/en/Xeris-Pharmaceuticals-Appoints-Mark-Thierer-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors2019-10-01T12:00:00Z<![CDATA[CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, has appointed Mark Thierer to its Board of Directors, increasing the size of the Board to seven members, effective immediately. Mr. Thierer will also be a member of the Audit Committee.]]>https://www.globenewswire.com/news-release/2019/09/27/1922074/0/en/Xeris-Pharmaceuticals-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=14773Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2019-09-27T20:05:00Z<![CDATA[CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on September 25, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 4,000 shares of its common stock to one new employee under Xeris’ Inducement Equity Plan.]]>